胃癌生物学标志物的相关研究进展
|
摘要
胃癌是发生于胃黏膜上皮的一种恶性肿瘤,是全世界恶性肿瘤中较为常见的一种。胃癌的诊断、预后、远期生存预测、转移及复发与一些生物学标志物有明显的相关性。因此,寻找一种敏感性较高、特异性较强的生物学标志物显得尤为重要。临床广泛使用的肿瘤标志物检测可协助胃癌的诊断,以早期发现胃癌,降低病死率,改善患者预后。目前人类表皮生长因子受体2、上皮钙黏素、肝细胞生长因子受体、微RNA均为热门胃癌生物学标志物。
Gastric cancer is a malignant tumor occurring in gastric mucosal epithelium and is a common type of malignant tumor in the world. The diagnosis,prognosis,long-term survival,metastasis and recurrence of gastric cancer are significantly correlated with some biological markers. Therefore,looking for a strong biological marker with high sensitivity and specificity is particularly important. The clinical use of tumor markers can improve the diagnosis of gastric cancer,in order to achieve early detection of gastric cancer,reduce the case fatality rate,and improve the prognosis of patients. At present,human epidermal growth factor receptor 2,E-cadherin,hepatocyte growth factor receptor,and microRNA are popular gastric cancer biomarkers.
Gastric cancer is a malignant tumor occurring in gastric mucosal epithelium and is a common type of malignant tumor in the world. The diagnosis,prognosis,long-term survival,metastasis and recurrence of gastric cancer are significantly correlated with some biological markers. Therefore,looking for a strong biological marker with high sensitivity and specificity is particularly important. The clinical use of tumor markers can improve the diagnosis of gastric cancer,in order to achieve early detection of gastric cancer,reduce the case fatality rate,and improve the prognosis of patients. At present,human epidermal growth factor receptor 2,E-cadherin,hepatocyte growth factor receptor,and microRNA are popular gastric cancer biomarkers.
引文
[1]Goetze OT,Al-Batran SE,Chevallay M.Multimodal treatment in locally advanced gastric cancer[J].Updates Surg,2018,70(2):173-179.
[2]Mahawongkajit P.A survey of early and advanced gastric cancer treatment by surgeons in Thailand[J].Oncol Rev,2018,12(2):369.
[3]Clinical implication of the innovations of the 8 edition of the TNMclassification for esophageal and esophago-gastric cancer[J].J Thorac Dis,2018,10(Suppl 22):S2671-2681.
[4]Fanotto V,Ongaro E,Rihawi K,et al.HER-2 inhibition in gastric and colorectal cancers:Tangible achievements,novel acquisitions and future perspectives[J].Oncotarget,2016,7(42):69060-69074.
[5]Shu S,Iimori M,Nakanishi R,et al.Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer[J].In Vivo(Athens,Greece),2018,32(6):1491-1498.
[6]Yan M,Schwaederle M,Arguello D,et al.HER2 expression status in diverse cancers:Review of results from 37,992 patients[J].Cancer Metastasis Rev,2015,34(1):157-164.
[7]Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2 scoring system for gastric cancer:Results from a validation study[J].Histopathology,2008,52(7):797-805.
[8]张俊,秦叔逵.HER2阳性晚期胃癌分子靶向治疗的中国专家共识(2016版)[J].临床肿瘤学杂志,2016,21(9):831-839.
[9]Cho J,Jeong J,Sung J,et al.A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages[J].Ann Surg Oncol,2013,20 Suppl 3:S477-484.
[10]Huang D,Lu N,Fan Q,et al.HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories:Chinese results of the HER-EAGLE study[J].PLo S One,2013,8(11):e80290.
[11]Qiu M,Zhou Y,Zhang X,et al.Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients[J].BMC Cancer,2014,14:823.
[12]Grabsch H,Sivakumar S,Gray S,et al.HER2 expression in gastric cancer:Rare,heterogeneous and of no prognostic valueconclusions from 924 cases of two independent series[J].Cell Oncol,2010,32(1/2):57-65.
[13]何中元,王桂芝,秦文华.胃癌组织HER-2基因的检测用于靶向治疗[J].医药论坛杂志,2014,35(9):36-37.
[14]Liang JW,Zhang JJ,Zhang T.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:A metaanalysis of the literature[J].Tumour Biol,2014,35(5):4849-4858.
[15]王文娜,罗健.晚期胃癌化疗及分子靶向治疗研究进展[J].中国医刊,2014,49(9):25-28.
[16]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(To GA):A phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[17]欧盟批准曲妥珠单抗联合化疗用于HER2阳性晚期胃癌[J].世界临床药物,2010,31(3):142.
[18]张闻辉,王舒宝.钙上皮黏附素在胃癌中的表达及其临床意义[J].黑龙江医学,2006,30(4):251-253.
[19]王锐,宋征宇,于永强,等.E-钙黏蛋白和VEGF在胃黏膜的表达及其相关性分析[J].现代消化及介入诊疗,2015,20(4):319-322.
[20]吴慧华,李曦,吴子刚.胃癌组织中S100A11、MMP-9及E-cadherin的表达及意义[J].临床和实验医学杂志,2018,17(3):268-270.
[21]米彩锋,牛丽林.E-钙黏蛋白、β-连环蛋白在胃癌中的表达及意义[J].中国社区医师,2016,32(7):132-133.
[22]Shino Y,Watanabe A,Yamada Y,et al.Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas[J].Cancer,1995,76(11):2193-2201.
[23]马钊,武华,尉瑞.E-cadherin、VEGF-C与胃癌临床病理学关系的研究[J].山西中医学院学报,2009,10(4):56-57.
[24]刘津,蔡建辉,阎庆辉.早期胃癌组织中上皮钙粘蛋白表达与淋巴结微转移及临床病理的关系[J].癌症,2007,26(5):541-546.
[25]Dures C,Almeida GM,Seruca R,et al.Biomarkers for gastric cancer:Prognostic,predictive or targets of therapy?[J].Virchows Arch,2014,464(3):367-378.
[26]袁波,喻学桥,周卫平,等.胃癌组织中成纤维细胞生长因子19和成纤维细胞生长因子受体4的表达及临床意义[J].中国现代医学杂志,2015,25(26):55-59.
[27]Lee HE,Kim MA,Lee HS,et al.MET in gastric carcinomas:Comparison between protein expression and gene copy number and impact on clinical outcome[J].Br J Cancer,2012,107(2):325-333.
[28]张成,高广荣,李达,等.蛋白酶激活受体-2活化对胃癌MKN28细胞血管内皮细胞生长因子基因及蛋白表达的影响[J].中国普外基础与临床杂志,2015,22(6):665-670.
[29]Pietrantonio F,De Braud F,Da Prat V,et al.A review on biomarkers for prediction of treatment outcome in gastric cancer[J].Anticancer Res,2013,33(4):1257-1266.
[30]Wu CW,Li AF,Chi CW,et al.Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma[J].Oncol Rep,1998,5(4):817-822.
[31]Amemiya H,Kono K,Mori Y,et al.High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein[J].Oncology,2000,59(2):145-151.
[32]Beppu K,Uchiyama A,Morisaki T,et al.Elevation of serum hepatocyte growth factor concentration in patients with gastric cancer is mediated by production from tumor tissue[J].Anticancer Res,2000,20(2B):1263-1267.
[33]Lamszus K,Jin L,Fuchs A,et al.Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice[J].Lab Invest,1997,76(3):339-353.
[34]Maehara N,Matsumoto K,Kuba K,et al.NK4,a four-kringle antagonist of HGF,inhibits spreading and invasion of human pancreatic cancer cells[J].Br J Cancer,2001,84(6):864-873.
[35]Esquela-Kerscher A.Oncomirs-microRNAs with a role in cancer[J].Nat Rev Cancer,2006,6(4):259-269.
[36]Zhang B,Pan X.MicroRNA:A new player in stem cells[J].J Cell Physiol,2006,209(2):266-269.
[37]邱光庭,王遂函,李大鹏,等.微小RNA-148a对胃癌细胞MKN45增殖能力的影响及机制研究[J].中华胃肠外科杂志,2014,17(10):1036-1039.
[38]Kong D,Li Y,Wang Z,et al.miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition,adhesion,and invasion of prostate cancer cells[J].Stem Cells,2009,27(8):1712-1721.
[39]Ding DP,Chen ZL,Zhao XH,et al.MiR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression[J].Carcinogenesis,2011,32(7):1025-1032.
[40]Feber A,Xi L,Luketich JD,et al.MicroRNA expression profiles of esophageal cancer[J].J Thorac Cardiovasc Surg,2008,135(2):255-260.
[41]黄培,曹建平.相关miRNA与胃癌发生及侵袭转移机制研究[J].现代肿瘤医学,2014,22(8):1968-1972.
[42]黄泽波.血清miRNA作为胃癌和食管鳞癌诊断标志物的研究[D].南京:南京医科大学,2017.
[43]Tsuchiya S,Fujiwara T,Sato F,et al.MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1[J].J Biol Chem,2011,286(1):420-428.
[44]Yuan Y,Zeng ZY,Liu XH,et al.MicroRNA-203 inhibits cell proliferation by repressing ANp63 expression in human esophageal Squamous cell carcinoma[J].BMC Cancer,2011,11:57.
[45]Ueda T,Volinia S,Okumura H,et al.Relation between microRNAexpression and progression and prognosis of gastric cancer:AmicroRNA expression analysis[J].Lancet Oncol,2010,11(12):136-146.
[46]Rugge M,Capelle LG.Individual risk stratification of gastric cancer:Evolving concepts and their impact on clinical practice[J].Best Pract Res Clin Gastroenterol,2014,28(6):1043-1053.
[2]Mahawongkajit P.A survey of early and advanced gastric cancer treatment by surgeons in Thailand[J].Oncol Rev,2018,12(2):369.
[3]Clinical implication of the innovations of the 8 edition of the TNMclassification for esophageal and esophago-gastric cancer[J].J Thorac Dis,2018,10(Suppl 22):S2671-2681.
[4]Fanotto V,Ongaro E,Rihawi K,et al.HER-2 inhibition in gastric and colorectal cancers:Tangible achievements,novel acquisitions and future perspectives[J].Oncotarget,2016,7(42):69060-69074.
[5]Shu S,Iimori M,Nakanishi R,et al.Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer[J].In Vivo(Athens,Greece),2018,32(6):1491-1498.
[6]Yan M,Schwaederle M,Arguello D,et al.HER2 expression status in diverse cancers:Review of results from 37,992 patients[J].Cancer Metastasis Rev,2015,34(1):157-164.
[7]Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2 scoring system for gastric cancer:Results from a validation study[J].Histopathology,2008,52(7):797-805.
[8]张俊,秦叔逵.HER2阳性晚期胃癌分子靶向治疗的中国专家共识(2016版)[J].临床肿瘤学杂志,2016,21(9):831-839.
[9]Cho J,Jeong J,Sung J,et al.A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages[J].Ann Surg Oncol,2013,20 Suppl 3:S477-484.
[10]Huang D,Lu N,Fan Q,et al.HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories:Chinese results of the HER-EAGLE study[J].PLo S One,2013,8(11):e80290.
[11]Qiu M,Zhou Y,Zhang X,et al.Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients[J].BMC Cancer,2014,14:823.
[12]Grabsch H,Sivakumar S,Gray S,et al.HER2 expression in gastric cancer:Rare,heterogeneous and of no prognostic valueconclusions from 924 cases of two independent series[J].Cell Oncol,2010,32(1/2):57-65.
[13]何中元,王桂芝,秦文华.胃癌组织HER-2基因的检测用于靶向治疗[J].医药论坛杂志,2014,35(9):36-37.
[14]Liang JW,Zhang JJ,Zhang T.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:A metaanalysis of the literature[J].Tumour Biol,2014,35(5):4849-4858.
[15]王文娜,罗健.晚期胃癌化疗及分子靶向治疗研究进展[J].中国医刊,2014,49(9):25-28.
[16]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(To GA):A phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[17]欧盟批准曲妥珠单抗联合化疗用于HER2阳性晚期胃癌[J].世界临床药物,2010,31(3):142.
[18]张闻辉,王舒宝.钙上皮黏附素在胃癌中的表达及其临床意义[J].黑龙江医学,2006,30(4):251-253.
[19]王锐,宋征宇,于永强,等.E-钙黏蛋白和VEGF在胃黏膜的表达及其相关性分析[J].现代消化及介入诊疗,2015,20(4):319-322.
[20]吴慧华,李曦,吴子刚.胃癌组织中S100A11、MMP-9及E-cadherin的表达及意义[J].临床和实验医学杂志,2018,17(3):268-270.
[21]米彩锋,牛丽林.E-钙黏蛋白、β-连环蛋白在胃癌中的表达及意义[J].中国社区医师,2016,32(7):132-133.
[22]Shino Y,Watanabe A,Yamada Y,et al.Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas[J].Cancer,1995,76(11):2193-2201.
[23]马钊,武华,尉瑞.E-cadherin、VEGF-C与胃癌临床病理学关系的研究[J].山西中医学院学报,2009,10(4):56-57.
[24]刘津,蔡建辉,阎庆辉.早期胃癌组织中上皮钙粘蛋白表达与淋巴结微转移及临床病理的关系[J].癌症,2007,26(5):541-546.
[25]Dures C,Almeida GM,Seruca R,et al.Biomarkers for gastric cancer:Prognostic,predictive or targets of therapy?[J].Virchows Arch,2014,464(3):367-378.
[26]袁波,喻学桥,周卫平,等.胃癌组织中成纤维细胞生长因子19和成纤维细胞生长因子受体4的表达及临床意义[J].中国现代医学杂志,2015,25(26):55-59.
[27]Lee HE,Kim MA,Lee HS,et al.MET in gastric carcinomas:Comparison between protein expression and gene copy number and impact on clinical outcome[J].Br J Cancer,2012,107(2):325-333.
[28]张成,高广荣,李达,等.蛋白酶激活受体-2活化对胃癌MKN28细胞血管内皮细胞生长因子基因及蛋白表达的影响[J].中国普外基础与临床杂志,2015,22(6):665-670.
[29]Pietrantonio F,De Braud F,Da Prat V,et al.A review on biomarkers for prediction of treatment outcome in gastric cancer[J].Anticancer Res,2013,33(4):1257-1266.
[30]Wu CW,Li AF,Chi CW,et al.Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma[J].Oncol Rep,1998,5(4):817-822.
[31]Amemiya H,Kono K,Mori Y,et al.High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein[J].Oncology,2000,59(2):145-151.
[32]Beppu K,Uchiyama A,Morisaki T,et al.Elevation of serum hepatocyte growth factor concentration in patients with gastric cancer is mediated by production from tumor tissue[J].Anticancer Res,2000,20(2B):1263-1267.
[33]Lamszus K,Jin L,Fuchs A,et al.Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice[J].Lab Invest,1997,76(3):339-353.
[34]Maehara N,Matsumoto K,Kuba K,et al.NK4,a four-kringle antagonist of HGF,inhibits spreading and invasion of human pancreatic cancer cells[J].Br J Cancer,2001,84(6):864-873.
[35]Esquela-Kerscher A.Oncomirs-microRNAs with a role in cancer[J].Nat Rev Cancer,2006,6(4):259-269.
[36]Zhang B,Pan X.MicroRNA:A new player in stem cells[J].J Cell Physiol,2006,209(2):266-269.
[37]邱光庭,王遂函,李大鹏,等.微小RNA-148a对胃癌细胞MKN45增殖能力的影响及机制研究[J].中华胃肠外科杂志,2014,17(10):1036-1039.
[38]Kong D,Li Y,Wang Z,et al.miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition,adhesion,and invasion of prostate cancer cells[J].Stem Cells,2009,27(8):1712-1721.
[39]Ding DP,Chen ZL,Zhao XH,et al.MiR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression[J].Carcinogenesis,2011,32(7):1025-1032.
[40]Feber A,Xi L,Luketich JD,et al.MicroRNA expression profiles of esophageal cancer[J].J Thorac Cardiovasc Surg,2008,135(2):255-260.
[41]黄培,曹建平.相关miRNA与胃癌发生及侵袭转移机制研究[J].现代肿瘤医学,2014,22(8):1968-1972.
[42]黄泽波.血清miRNA作为胃癌和食管鳞癌诊断标志物的研究[D].南京:南京医科大学,2017.
[43]Tsuchiya S,Fujiwara T,Sato F,et al.MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1[J].J Biol Chem,2011,286(1):420-428.
[44]Yuan Y,Zeng ZY,Liu XH,et al.MicroRNA-203 inhibits cell proliferation by repressing ANp63 expression in human esophageal Squamous cell carcinoma[J].BMC Cancer,2011,11:57.
[45]Ueda T,Volinia S,Okumura H,et al.Relation between microRNAexpression and progression and prognosis of gastric cancer:AmicroRNA expression analysis[J].Lancet Oncol,2010,11(12):136-146.
[46]Rugge M,Capelle LG.Individual risk stratification of gastric cancer:Evolving concepts and their impact on clinical practice[J].Best Pract Res Clin Gastroenterol,2014,28(6):1043-1053.